Hepatic complications of hematopioetic cell transplantation

Current Gastroenterology Reports

Volumn 9, Issue 1, 2007, Pages 60-65

  Levitsky, Josh ^a   Sorrell, Michael F ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; ADEFOVIR; AMPHOTERICIN B; ANTITHROMBIN III; BUSULFAN; CIDOFOVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFIBROTIDE; ECHINOCANDIN; ENTECAVIR; FOSCARNET; GANCICLOVIR; GEMTUZUMAB OZOGAMICIN; HEPARIN; INTERFERON; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PYRROLE DERIVATIVE; RAPAMYCIN; RIBAVIRIN; RITUXIMAB; TACROLIMUS; TENOFOVIR; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; CHICKENPOX; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG MEGADOSE; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS G; HERPES SIMPLEX; HERPES VIRUS INFECTION; HUMAN; IRON OVERLOAD; LABORATORY TEST; LIVER BIOPSY; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER SINUSOID; LIVER TOXICITY; MYCOSIS; PROGNOSIS; REVIEW; SEPSIS; TOTAL PARENTERAL NUTRITION; UNSPECIFIED SIDE EFFECT; BILIARY TRACT DISEASE; DRUG TOXICITY; LIVER VEIN OBSTRUCTION; RISK FACTOR; VIRUS HEPATITIS;

BILIARY TRACT DISEASES; DRUG TOXICITY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HEPATITIS, VIRAL, HUMAN; HUMANS; IRON OVERLOAD; LIVER DISEASES; MYCOSES; PARENTERAL NUTRITION, TOTAL; RISK FACTORS; SEPSIS;

EID: 33947696700     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0022-y     Document Type: Review

References (45)

1. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB: Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005, 41:345-352.
2. Litzow MR, Repoussis PD, Schroeder G, et al.: Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma 2002, 43:2099-2107.
3. Strasser SI, Sullivan KM, Myerson D, et al.: Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999, 93:3259-3266.
4. Shulman HM, Gooley T, Dudley MD, et al.: Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995, 59:1015-1022.
5. Lau GK, Leung YH, Fong DY, et al.: High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99:2324-2230.
6. Chen PM, Yao NS, Wu CM, et al.: Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation 2002, 74:182-188.
7. Ustun C, Idilman R, Gurman G, et al.: Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe. J Hepatol 1999, 31:202-209.
8. Lau GK, He ML, Fong DY, et al.: Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoictic cell transplantation. Hepatology 2002, 36:702-709.
9. Nakagawa M, Simizu Y, Suemura M, Sato B: Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases. Am J Hematol 2002, 70:60-63.
10. Tomas JF, Pinilla I, Garcia-Buey ML, et al.: Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 2000, 26:649-655.
11. Strasser SI, Myerson D, Spurgeon CL, et al.: Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999, 29:1893-1899.
12. Frickhofen N, Wiesneth M, Jainta C, et al.: Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994, 83:1998-2004.
13. Peffault DL, Levy V, Asselah T, et al.: Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004, 103:1618-1624.
14. Ljungman P, Johansson N, Aschan J, et al.: Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995, 86:1614-1618.
15. Fujii Y, Kaku K, Tanaka M, et al.: Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994, 13:523-526.
16. Giardini C, Galimberti M, Lucarelli G, et al.: Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Bone Marrow Transplant 1997, 20:767-772.
17. Gruson D, Hilbert G, Le Bail B, et al.: Fulminant hepatitis due to herpes simplex virus-type 2 in early phase of bone marrow transplantation. Hematol Cell Ther 1998, 40:41-44.
18. Koc Y, Miller KB, Schenkein DP, et al.: Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant, 2000, 6:44-49.
19. Yagi T, Karasuno T, Hasegawa T, et al.: Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000, 25:1003-1005.
20. Lucas SB: Other viral and infectious diseases and HIV-related liver disease. In Pathology of the Liver. Edited by MacSween RNM, Burt AD, Portmann BC, et al.: Edinburg: Churchill Livingstone, 2002:363-414.
21. Hoshino Y, Kimura H, Tanaka N, et al.: Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001, 115:105-111.
22. Gartner BC, Schafer H, Marggraff K, et al.: Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor post-transplant lymphoproliferative disease. J Clin Microbiol 2002, 40:351-358.
23. Bowden RA, Slichter SJ, Sayers M, et al.: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598-3603.
24. Winston DJ, Yeager AM, Chandrasekar PH, et al.: Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003, 36:749-758.
25. Peggs KS, Mackinnon S: Clinical trials with CMV-specific T cells. Cytotherapy 2002, 4:21-28.
26. Clark DA, Emery VC, Griffiths PD: Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients. Semin Hematol 2003, 40:154-162.
27. Wang WH, Wang HL: Fulminant adenovirus hepatitis following bone marrow transplantation. A case report and brief review of the literature. Arch Pathol Lab Med, 2003 127:e246-e248.
28. Skidmore SJ, Collingham KE, Harrison P, et al.: High prevalence of hepatitis G virus in bone marrow transplant recipients and patients treated for acute leukemia. Blood 1997, 89:3853-3856.
29. Karayiannis P, Hadziyannis SJ, Kim J, et al.: Hepatitis G virus infection: clinical characteristics and response to interferon. J Viral Hepat 1997, 4:37-44.
30. Moseley RH: Scpsis-associated cholestasis. Gastroenterology 1997, 112:302-306.
31. Wolff SN, Fay J, Stevens D, et al.: Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000, 25:853-859.
32. Carreras E, Granena A, Navasa M, et al.: Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993, 11:21-26.
33. Ruutu T, Eriksson B, Remes K, et al.: Ursodeoxycholic acid for the prevention of hepatic complications in allogencic stem cell transplantation. Blood 2002, 100:1977-1983.
34. Kanojia MD, Anagnostou AA, Zander AR, et al.: High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984, 37:246-249.
35. Strasser SI, Shulman HM, Flowers ME, et al.: Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology 2000, 32:1265-1271.
36. Barshes NR, Myers GD, Lee D, et al.: Liver transplantation for severe hepatic graft-versus-host disease: An analysis of aggregate survival data. Liver Transpl 2005, 11:525-531.
37. McDonald GB, Hinds MS, et al.: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255-267.
38. Shulman HM, Gooley T, Dudley MD, et al.: Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995, 59:1015-1022.
39. Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987, 127:549-558.
40. Pegram AA, Kennedy LD: Prevention and treatment of veno-occlusive disease. Ann Pharmacother 2001, 35:935-942.
41. Richardson PG, Murakami C, Jin Z, et al.: Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
42. Corbacioglu S, Greil J, Peters C, et al.: Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004, 33:189-195.
43. Angelucci E, Muretto P, Lucarelli G, et al.: Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997, 90:994-998.
44. Murakami CS, Louie W, Chan GS, et al.: Biliary obstruction in hematopoictic cell transplant recipients: an uncommon diagnosis with specific causes. Bone Marrow Transplant 1999, 23:921-927.
45. Snover DC, Weisdorf S, Bloomer J, et al.: Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology 1989, 9:443-448.